
Loading, please wait...

Loading, please wait...

New research highlights a crucial link between inhaled steroids spine surgery outcomes. A collaborative study by Johns Hopkins University and AIIMS Delhi reveals significant risks for pulmonary patients. Specifically, asthma patients using regular inhalers are three times more likely to require repeat operations after spinal fusion. Interestingly, researchers discovered that asthma itself does not cause this increased risk. Instead, the prolonged use of steroid-based inhalers appears to be the primary factor affecting surgical success.
Spinal fusion success depends heavily on robust bone healing. Although oral steroids are known to weaken bones, the effect of inhaled versions was previously unclear. This study demonstrates that even these topical medications can compromise bone density. Consequently, patients using inhalers often experience poor fusion and implant-related issues. Because India has a high prevalence of under-recognised osteoporosis, these findings are particularly critical. Therefore, doctors must identify at-risk patients early to prevent long-term complications.
Patients should not stop their asthma treatments abruptly. However, clinicians must focus on smarter spine care strategies for these individuals. Identifying at-risk individuals before surgery allows for better bone health optimization. For instance, pre-operative evaluations should assess bone density and manage treatments carefully. This approach is vital given the rising elderly population and increasing air pollution. Furthermore, managing the underlying bone weakness can significantly improve long-term surgical success. Thus, coordination between pulmonologists and surgeons becomes essential for patient safety.
Q1: Why do asthma inhalers increase spine surgery risks?
Inhaled steroids can subtly weaken bone structure and slow the healing process required for successful spinal fusion, leading to potential implant failures.
Q2: Should patients stop using their inhalers before surgery?
No, patients should continue their medication under strict medical guidance. The goal is to optimize bone health and respiratory stability rather than stopping essential treatment.
Q3: How can doctors improve outcomes for these patients?
Early pre-operative evaluation and optimizing bone health through supplements or lifestyle changes can help mitigate the risks associated with steroid use.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Long-term use of inhaled steroids can triple the risk of repeat spine surgery. Learn how optimizing bone health improves outcomes for asthma patients....
5 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today